% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Schneider:307503,
author = {F. Schneider and H. Chen and U. Pelzer and R. G. Compton
and G. Duwe and M. P. Dragomir$^*$ and G. Hilfenhaus and L.
Vecchione and A. Alig and M. Felsenstein and M. Lerchbaumer
and D. T. Rieke and M. Bahra and R. Kutsche and K. Tschulik
and S. Stintzing and U. Keilholz and C. C. M. Neumann},
title = {{T}he basis for future personalized therapy approaches -
{M}achine learning-generated 1-year survival rate,
metastatic status and therapy-dependent survival in
pancreatic cancer patients.},
journal = {European journal of cancer},
volume = {234},
issn = {0959-8049},
address = {Amsterdam [u.a.]},
publisher = {Elsevier},
reportid = {DKFZ-2026-00008},
pages = {116189},
year = {2026},
abstract = {Pancreatic adenocarcinoma (PDAC) remains one of the most
lethal types of cancer, characterized by its unspecific
symptoms, aggressive nature and late-stage diagnosis.In this
study, Machine Learning (ML) models were trained and applied
on the largest international, monocentric database,
comprising over 23 clinical variables from 1040 PDAC
patients. In this study, the potential of ML models was
assessed for the 1-year survival rate, metastatic M0/M1
status and therapy-dependent survival time generating
predictive and prognostic ML-based biomarkers.Consistent
predictive performance was achieved for the 1-year survival
rate (accuracy, internal/external cohort 72 $\%$ / 70 $\%)$
and radiological metastatic M0/M1 status (Accuracy,
internal/external cohort 79 $\%$ / 72 $\%).$ Moreover,
distinct ML-based survival models were trained for approved
first-line adjuvant and palliative chemotherapy regimen
(mFOLFIRINOX, gemcitabine with or without nab-paclitaxel)
across resected (C-index = 0.60), locally advanced (C-index
= 0.71) and metastatic (C-index = 0.71) PDAC subgroups,
demonstrating that predictive performance is best for
palliative regimens.The models developed in this study may
serve as a foundation for supporting tumor board decisions
and demonstrate that personalized, ML-based therapy concepts
are feasible in the near future. In addition, the models
proposed in this study are helpful for generating ML-based
synthetic control arms in future clinical trials.},
keywords = {Clinical Decision Suppor (Other) / Gradient Boosting
(Other) / Machine learning (Other) / Model Interpretation
(Other) / Oncology (Other) / Pancreatic cancer (Other) /
Personalized medicine (Other) / Prognostic modeling (Other)
/ Random Forest (Other) / Random Survival Forest (Other) /
Scenario-Based Simulation (Other) / Survival analysis
(Other) / Survival prediction (Other) / Treatment Simulation
(Other)},
cin = {BE01},
ddc = {610},
cid = {I:(DE-He78)BE01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41468770},
doi = {10.1016/j.ejca.2025.116189},
url = {https://inrepo02.dkfz.de/record/307503},
}